CancerFax
DATA & COMPARISON · PROSTATE ONCOLOGY

ENZALUTAMIDE VS ABIRATERONE
VS DAROLUTAMIDE

Three next-generation androgen receptor signalling inhibitors (ARSIs) — enzalutamide, abiraterone, and darolutamide — have each demonstrated overall survival benefit in Phase III trials. They are not interchangeable: differences in mechanism, CNS penetration, drug interactions, and tolerability guide individualised selection.

analyticsAt a Glance

  • check_circleAll three extend overall survival in metastatic hormone-sensitive prostate cancer (mHSPC) when added to ADT
  • check_circleAbiraterone requires concurrent prednisone to replace adrenal glucocorticoids — enzalutamide and darolutamide do not require steroids
  • check_circleDarolutamide has the lowest CNS penetration — fewer CNS-related side effects (seizure, fatigue, falls) than enzalutamide
  • check_circleEnzalutamide has the most CYP enzyme interactions; darolutamide the fewest — relevant for polypharmacy patients
Reviewed by: CancerFax Medical Team, Oncology & Haematology SpecialistsLast reviewed: June 4, 2026

How Each Agent Works: Three Approaches to Androgen Receptor Signalling Inhibition

All three agents suppress androgen receptor (AR) signalling — but at different points in the pathway. Understanding the mechanistic differences explains the different toxicity profiles and why the same disease can be treated with different approaches.

Abiraterone turns off androgen production upstream; enzalutamide and darolutamide block the receptor directly. Both strategies converge on the same goal — but the consequences of where in the pathway you intervene determine the side-effect landscape.
  • Abiraterone (Zytiga / Yonsa): CYP17A1 Inhibition

    Abiraterone inhibits CYP17A1 — the enzyme responsible for androgen synthesis in the testes, adrenal glands, and prostate tumour itself. By blocking this enzyme, abiraterone reduces testosterone and the potent androgen DHEA to near-undetectable levels. The downside: CYP17A1 is also involved in cortisol synthesis — blocking it triggers a compensatory ACTH rise that causes mineralocorticoid excess (hypertension, hypokalaemia) and glucocorticoid deficiency, requiring co-prescription of prednisone 5 mg twice daily or once-daily methylprednisolone.

  • Enzalutamide (Xtandi): Multi-Step Androgen Receptor Blockade

    Enzalutamide blocks the AR at three steps: it prevents androgen binding to the receptor, blocks AR nuclear translocation, and inhibits AR-DNA binding. Compared to first-generation anti-androgens (bicalutamide), it has 5–8× greater affinity and no partial agonist activity — functioning as a pure AR antagonist. It crosses the blood-brain barrier, which contributes to efficacy in brain-metastasis settings but also causes CNS side effects including fatigue, cognitive slowing, and a 0.5–1% seizure risk.

  • Darolutamide (Nubeqa): High AR Affinity, Low CNS Penetration

    Darolutamide binds the AR with high affinity — including some enzalutamide-resistant AR mutations (particularly F877L) — and is a pure AR antagonist without partial agonism. Its unique structural characteristic is minimal blood-brain barrier penetration: CNS darolutamide levels are approximately 30× lower than enzalutamide. This substantially reduces CNS-related side effects — seizure risk, fatigue, falls, and cognitive effects — making it the preferred AR antagonist for patients at risk of CNS side effects.

Efficacy Comparison: Overall Survival Benefit in Metastatic HSPC

All three agents have demonstrated OS benefit in metastatic hormone-sensitive prostate cancer (mHSPC) when added to ADT — the most common initial systemic treatment context for these drugs.

OS Benefit: ADT + ARSI vs ADT Alone — Phase III mHSPC Trials

ENZAMET (enzalutamide), LATITUDE (abiraterone), ARCHES (enzalutamide), TITAN (apalutamide), ARASENS (darolutamide); approximate median OS or hazard ratios

  • ADT + Darolutamide: OS HR vs ADT + docetaxel (ARASENS)HR 0.68 (32% reduction)
  • ADT + Enzalutamide: mOS improvement vs ADT alone (ENZAMET)HR 0.66 (34% reduction)
  • ADT + Abiraterone: mOS improvement vs ADT alone (LATITUDE)HR 0.62 (38% reduction)

Enzalutamide vs Abiraterone vs Darolutamide: Head-to-Head Comparison

No direct head-to-head randomised trial compares these three agents — selection is based on clinical characteristics, tolerability, and practical factors.

ParameterEnzalutamide (Xtandi)Abiraterone (Zytiga/Yonsa)Darolutamide (Nubeqa)
MechanismAR antagonist — blocks binding, nuclear translocation, DNA bindingCYP17A1 inhibitor — blocks androgen synthesisAR antagonist — high affinity, also binds F877L mutant AR
Steroid co-prescriptionNot requiredRequired — prednisone 5 mg BD (or methylprednisolone 4 mg OD with Yonsa)Not required
CNS penetrationHigh — significant BBB penetrationModerateVery low — ~30× less than enzalutamide
Seizure risk~0.5–1% (higher with prior seizure history)Very low (<0.1%)Not significantly elevated above background
Fatigue (Grade ≥2)Moderate–high (35–40%)Moderate (16–20%)Lower than enzalutamide (~12–15%)
Falls and fracturesHigher vs abiraterone — CNS-mediatedLowerLowest of the three — CNS advantage
Hypertension / hypokalaemiaNot a primary concernSignificant — requires regular BP and potassium monitoringNot a primary concern
Liver toxicity (ALT/AST)Uncommon — monitor LFTs at baselineMore common (5–10%) — requires regular LFT monitoringUncommon
Drug interactions (CYP)Strong CYP3A4 and CYP2C8 inducer — many interactionsStrong CYP3A4 and CYP2D6 inhibitor — many interactionsFewer interactions; CYP3A4 substrate but weaker inhibition
Approved indicationsmHSPC + ADT; nmCRPC; mCRPC after docetaxel or without prior chemotherapymHSPC + ADT + prednisone; mCRPC after failed ADTnmCRPC + ADT (ARAMIS); mHSPC + ADT + docetaxel (ARASENS)
Preferred whenmCRPC after abiraterone failure (sequential); no seizure risk; brain metsCV low-risk; no steroid contraindication; post-chemo CRPCHigh seizure risk; CNS-sensitive patients; polypharmacy; cognitive concern

Clinical Selection Guide: When to Prefer Each Agent

In the absence of head-to-head data, the following clinical scenarios guide selection between these three ARSIs.

Prefer Darolutamide When

  • Prior seizure history or epilepsyDarolutamide's minimal CNS penetration means it does not lower the seizure threshold — the primary reason to prefer it over enzalutamide in patients with seizure history or risk.
  • Polypharmacy patients with CYP interactionsDarolutamide has the lowest drug interaction burden of the three — important for patients on anticoagulants, antiepileptics, statins, and multiple cardiac medications.
  • Falls or cognitive fragility riskIn older or frail patients where falls risk is significant, darolutamide's CNS-sparing profile reduces the risk of dizziness, balance problems, and falls compared to enzalutamide.
  • Fatigue is a primary quality-of-life concernDarolutamide consistently shows lower fatigue rates than enzalutamide — relevant when energy and daily function are priorities for the patient.

Prefer Abiraterone When

  • No contraindication to prednisoneAbiraterone requires prednisone — patients with well-controlled diabetes, osteoporosis, or chronic infections may have steroid concerns; those without these issues tolerate prednisone well.
  • Post-docetaxel CRPC (established evidence)Abiraterone was approved earlier in the CRPC setting — there is more long-term CRPC data with abiraterone than with the other two agents in this disease stage.
  • mHSPC with hypertension already managedIf blood pressure is already controlled with medication, adding abiraterone-related hypertension to a managed cardiovascular profile is clinically manageable.
  • Lower cost or better access in some marketsAbiraterone now has generic versions (abiraterone acetate) available — in cost-sensitive settings, generic abiraterone + prednisone may be substantially cheaper than branded enzalutamide or darolutamide.

Key Numbers Across the Three Agents

Reference figures from the pivotal trials and clinical practice.

  • 30–38%Relative OS reduction with ADT + ARSI vs ADT alone (mHSPC)Consistent across ENZAMET, LATITUDE, and ARASENS trials — all three ARSIs provide meaningful overall survival benefit when added to ADT in hormone-sensitive metastatic disease.
  • 30×Lower CNS drug level: darolutamide vs enzalutamideThe structural property that makes darolutamide the CNS-sparing option — this difference directly translates to lower rates of fatigue, seizure, falls, and cognitive effects.
  • 5 mg BDPrednisone dose required with abiraterone (standard formulation)Replaces the adrenal glucocorticoids suppressed by CYP17A1 inhibition. Yonsa (micronised abiraterone) can be taken with methylprednisolone 4 mg once daily — lower total steroid dose.
  • ~1%Seizure risk with enzalutamide (background prostate cancer population)Low in absolute terms but clinically significant — enzalutamide is not recommended in patients with prior seizure history, CNS metastases without prophylactic AEDs, or recent stroke.

Frequently Asked Questions

Common questions from patients comparing next-generation prostate cancer hormonal therapies.

Choosing Between ARSIs

  • My urologist prescribed abiraterone but I have diabetes — should I be concerned about the prednisone?

    Prednisone 5 mg twice daily is a low-dose glucocorticoid, but in patients with diabetes, even low-dose steroids can worsen glycaemic control. Key considerations: (1) HbA1c and fasting glucose should be measured before starting abiraterone + prednisone; (2) your diabetes medications may need adjustment when prednisone is started; (3) glucose monitoring should be more frequent in the first 4–8 weeks; (4) Yonsa (micronised abiraterone) taken with food uses a lower steroid dose — methylprednisolone 4 mg once daily rather than prednisone 10 mg daily total — which may be preferable if glycaemic control is a concern. If these measures do not adequately manage the added glycaemic challenge, darolutamide or enzalutamide — neither requiring steroid co-prescription — are pharmacologically equivalent alternatives for mHSPC.

  • Can I take abiraterone and enzalutamide together?

    No — combining abiraterone and enzalutamide is not standard practice and has not been shown to improve outcomes versus either agent alone. They have overlapping but distinct mechanisms (androgen synthesis inhibition vs androgen receptor blockade) and have been studied in sequence rather than combination in most clinical trial programs. The STAMPEDE trial showed no benefit from sequential combination. The current standard is to choose one ARSI at each treatment line based on disease stage, prior treatment, and tolerability — and to switch to the other (or to a different drug class) at progression.

How CancerFax Helps

CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.

description
Medical Record Review

We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.

verified_user
Eligibility Coordination

We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.

hub
Hospital Communication

We support appointment coordination, document submission, translation, and direct communication with international departments.

flight
Travel & Admission Support

For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.

explore
Treatment & Trial Navigation

If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.

support_agent
End-to-end Coordination

From inquiry through to follow-up, our coordinators provide a single point of contact for the family.

CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

Which Next-Generation Hormonal Agent Is Right for You?

CancerFax connects patients with specialist prostate oncologists who can review your disease stage, PSA trajectory, comorbidities, and current medications to recommend the most appropriate ARSI for your specific clinical situation.

This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.